- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | CNS Pharmaceuticals reports Q2 results | 1 | Seeking Alpha | ||
| Fr | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Update | 280 | ACCESS Newswire | Strong cash position of $12.1 million expected to fund operations into the second half of 2026Driving lead program, TPI 287, towards Phase 2 study for treatment of glioblastoma multiforme (GBM) HOUSTON... ► Artikel lesen | |
| 14.08. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech | 248 | ACCESS Newswire | - Live video webcast on Tuesday, August 19th at 2:40 PM ET HOUSTON, TX / ACCESS Newswire / August 14, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company... ► Artikel lesen | |
| 22.07. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals to Participate in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference | 238 | ACCESS Newswire | - Video webcast now available on-demand HOUSTON, TX / ACCESS Newswire / July 22, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in... ► Artikel lesen | |
| CNS PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 22.07. | XFRA BE50: AUSSETZUNG/SUSPENSION | 221 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILCNS PHARM.INC.NEW... ► Artikel lesen | |
| 22.07. | XFRA NEW INSTRUMENTS AVAILABLE ON 22.07.2025 | 692 | Xetra Newsboard | The following instruments on XETRA do have their first trading 22.07.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 22.07.2025
Aktien
1 NGGTCO000002 Guaranty Trust Holding... ► Artikel lesen | |
| 21.07. | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 21.07.2025 | 337 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 21.07.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 21.07.2025ISIN NameCA7703631092 ROBERTO... ► Artikel lesen | |
| 21.07. | XFRA ISIN CHANGE | 356 | Xetra Newsboard | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenUS18978H4092 CNS Pharmaceuticals Inc. 21.07.2025 US18978H5081 CNS Pharmaceuticals Inc. 22.07.2025 Tausch 12:1CA86218J2048 Storm... ► Artikel lesen | |
| 18.07. | CNS Pharmaceuticals announces 1-for-12 reverse stock split | 4 | Investing.com | ||
| 18.07. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Announces Reverse Stock Split | 236 | ACCESS Newswire | HOUSTON, TX / ACCESS Newswire / July 18, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for... ► Artikel lesen | |
| 15.07. | CNS Pharmaceuticals, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 09.07. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Participates in Virtual Investor CEO Connect Segment | 386 | ACCESS Newswire | HOUSTON, TX / ACCESS Newswire / July 9, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary... ► Artikel lesen | |
| 24.06. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment Discussing Glioblastoma Multiforme and Lead Product Candidate TPI 287 | 221 | ACCESS Newswire | Moderated discussion with founding physician of the Brain Tumor Center and Director of Neuro-Oncology at Piedmont Atlanta Hospital, Dr. Erin Dunbar HOUSTON, TX / ACCESS Newswire / June 24, 2025 / CNS... ► Artikel lesen | |
| 05.06. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals' Chief Medical Officer, Sandra Silberman, MD, PhD to Present at the 2025 Brain Tumor Biotech Summit | 317 | ACCESS Newswire | In person presentation today, Thursday, June 5th at 9:30 AM ET to discuss Company's lead program, TPI 287, in development for treatment of glioblastoma multiforme (GBM) HOUSTON, TX / ACCESS Newswire... ► Artikel lesen | |
| 16.05. | CNS Pharmaceuticals reports Q1 results | 4 | Seeking Alpha | ||
| 16.05. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update | 431 | ACCESS Newswire | Cash expected to fund operations into the second half of 2026Advancing development strategy for lead program TPI 287 to commence Phase 2 study around year end 2025 for treatment of glioblastoma multiforme... ► Artikel lesen | |
| 15.05. | CNS Pharmaceuticals, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 13.05. | CNS Pharmaceuticals Stock Surges 36% On $5 Mln Public Offering Announcement | 1 | RTTNews | ||
| 13.05. | CNS Pharmaceuticals sets terms for $5 million stock offering | 3 | Investing.com | ||
| 13.05. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules | 700 | ACCESS Newswire | HOUSTON, TX / ACCESS Newswire / May 13, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary... ► Artikel lesen |
1 2 3 4 Weiter >>
64 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CUREVAC | 4,650 | -0,56 % | EQS-News: CureVac veröffentlicht Finanzergebnisse für das zweite Quartal sowie das erste Halbjahr 2025 und informiert über seine Geschäftsentwicklung | Emittent / Herausgeber: CureVac
/ Schlagwort(e): Quartalsergebnis
CureVac veröffentlicht Finanzergebnisse für das zweite Quartal sowie das erste Halbjahr 2025 und informiert... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | - | - | Boehringer Ingelheim Limited: Boehringer Ingelheim and Palatin Technologies to develop potential first-in-class melanocortin receptor targeted treatment for patients with retinal diseases | · Collaboration strengthens Boehringer's pipeline in Eye Health.· Many patients with diabetic retinopathy (DR) continue to experience vision loss or treatment fatigue, underscoring an... ► Artikel lesen | |
| BIOXXMED | 0,600 | 0,00 % | EQS-News: bioXXmed AG informiert über die Verzögerung der Veröffentlichung des geprüften Jahresabschlusses 2024 | EQS-News: bioXXmed AG
/ Schlagwort(e): Jahresbericht
bioXXmed AG informiert über die Verzögerung der Veröffentlichung des geprüften Jahresabschlusses 2024
27.06.2025 /... ► Artikel lesen | |
| VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer | SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim Labs"), a pharmaceutical and biotechnology services company that is focused on providing testing... ► Artikel lesen | |
| OCUGEN | 0,862 | -0,99 % | Ocugen - Novel cell therapies for retinal diseases | Ocugen's modifier gene therapy (MGT) platform is designed to regulate gene expression to restore visual function across both genetically diverse inherited retinal diseases (IRDs) and retinal conditions... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem Corp.: Sirona Biochem Update to Shareholders on Financial Status and Operations | VANCOUVER, British Columbia, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) ("Sirona") wishes to provide shareholders with a critical update on the company's financial... ► Artikel lesen | |
| BIO-GATE | 0,970 | +2,65 % | EQS-Adhoc: Bio-Gate AG: Bio-Gate AG beschließt Ausgabe einer Wandelschuldverschreibung unter Ausschluss des Bezugsrechts | EQS-Ad-hoc: Bio-Gate AG / Schlagwort(e): Kapitalmaßnahme/Sonstiges
Bio-Gate AG: Bio-Gate AG beschließt Ausgabe einer Wandelschuldverschreibung unter Ausschluss des Bezugsrechts
19.08.2025... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,365 | -1,08 % | Defence Therapeutics Inc.: Defence's Accum Technology with ADC and Radiopharmaceutical Programs Target Cancer | Montreal, Quebec--(Newsfile Corp. - July 14, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug... ► Artikel lesen | |
| VAXART | 0,292 | 0,00 % | Vaxart outlines accelerated COVID-19 trial data timeline and plans norovirus Phase IIb pending funding | ||
| BURCON NUTRASCIENCE | 1,610 | +2,55 % | Burcon NutraScience Corporation: Burcon Announces Fiscal 2026 First Quarter Results | Vancouver, British Columbia--(Newsfile Corp. - August 13, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in plant-based protein... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 4,300 | 0,00 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update | Intend to Pursue an NDA Submission to the U.S. FDA under Accelerated Approval Pathway for Iopofosine I 131 for the Treatment of Waldenstrom Macroglobulinemia (WM) Subject to Sufficient Funding and... ► Artikel lesen | |
| AFFIMED | 0,972 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 28.05.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 28.05.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 28.05.2025ISIN NameBMG3728V1090 GAN... ► Artikel lesen | |
| IMMUNIC | 0,770 | -1,79 % | EQS-News: Immunic AG: Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update | Issuer: Immunic AG
/ Key word(s): Quarter Results
Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update
07.08.2025 / 12:30 CET/CEST
The... ► Artikel lesen | |
| AIM IMMUNOTECH | 0,073 | -100,00 % | AIM ImmunoTech Inc.: AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update | Continued progress across pipeline programs with focus on pancreatic cancer Mid-year report of Ampligen® (rintatolimod) in combination with AstraZeneca's Imfinzi® (durvalumab) for the treatment... ► Artikel lesen | |
| T2 BIOSYSTEMS | 0,250 | 0,00 % | NSE/A - T2 Biosystems, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities |
CNS PHARMACEUTICALS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 7,040 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CNS PHARMACEUTICALS INC finden Sie auf Wallstreet Online.